Literature DB >> 12184369

Overview of vaccine adjuvants: present and future.

Robert L Hunter1.   

Abstract

The history of infectious diseases together with the evidence of emerging and reemerging infections underscores the need for new vaccines and the obstacles to producing them. Vaccine adjuvants are usually thought of as agents that increase the intensity of immune responses and influence the balance between antibody and cell-mediated immunity at the cost of toxicity. This review uses copolymer adjuvants as examples to encourage a more sophisticated approach to the study of adjuvants as agents that can influence many parameters of immune responses including the specificity, titer, duration, memory, class, isotype, and avidity of antibody as well as the type of cell-mediated immunity and the incidence of genetic non-responders. Much research will be needed for design of effective vaccines against emerging and reemerging infections and for improvement of existing vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12184369     DOI: 10.1016/s0264-410x(02)00164-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.

Authors:  Camilo Cuadros; Francisco J Lopez-Hernandez; Ana Lucia Dominguez; Michael McClelland; Joseph Lustgarten
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

2.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 3.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

4.  Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.

Authors:  George Hui; Dan Choe; Caryn Hashimoto
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

5.  Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Authors:  Ellen S Vitetta; Joan E Smallshaw; John Schindler
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

6.  Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.

Authors:  Rohan S Ingrole; Wenqian Tao; Jatindra N Tripathy; Harvinder S Gill
Journal:  Nano Life       Date:  2014-06-01

7.  Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses.

Authors:  Oscar Pino; Michael Martin; Suzanne M Michalek
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Authors:  Andrei Soliakov; Ian F Kelly; Jeremy H Lakey; Allan Watkinson
Journal:  Eur J Pharm Biopharm       Date:  2011-09-22       Impact factor: 5.571

9.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

Review 10.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.